Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that was shown in multiple clinical trials to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : $23.6 million
August 09, 2021
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Announces Enrollment and Financing of Covid-19 Cohort in Phase III Revival Trial
Details : The REVIVAL Phase III pivotal trial is a randomized, double-blind, placebo-controlled, two-arm, parallel-group, multi-center trial to evaluate the efficacy and safety of AM-Pharma’s proprietary human recombinant alkaline phosphatase for the treatment o...
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable